The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Juno Therapeutics, Inc. (“Juno
Therapeutics” or the “Company”) (NASDAQ:JUNO) stock prior
to January 22, 2018.
You are hereby notified that Levi & Korsinsky, LLP has commenced
an investigation into the fairness of the sale
of Juno Therapeutics to Celgene Corporation (NASDAGS: CELG) for $87
per share. To learn more about the action and your rights, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or
by telephone at (212) 363-7500, toll-free: (877) 363-5972. There
is no cost or obligation to you.
The investigation concerns whether the Board of Juno Therapeutics
breached their fiduciary duties to stockholders by failing to adequately
shop the Company before agreeing to enter into this transaction, and
whether Celgene Corporation is underpaying for Juno Therapeutics shares,
thus unlawfully harming Juno Therapeutics shareholders.
Levi & Korsinsky is a national firm with offices in New York,
Connecticut, California, and Washington D.C. The firm's attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities lawsuits and have recovered hundreds of millions of
dollars for aggrieved shareholders. For more information, please
feel free to contact any of the attorneys listed below. Attorney
advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180123005350/en/